Revenue fell 83.0% to KRW 111 million in 2025 from KRW 6.5 million... more precisely, from KRW 655 million in 2024. Over the same period, the operating loss widened from KRW 12.6 billion to KRW 28 billion, and the operating margin moved from -1,924.8% to -25,182.0%.
The key feature of 2025 is that the operating loss grew while revenue shrank sharply. Net loss attributable to controlling shareholders rose from KRW 5.69 billion to KRW 27.4 billion, and net loss including non-controlling interests was reported at the same amounts.
In 2025 the operating loss and the controlling-shareholder net loss were nearly equal, so non-operating items had little effect on the bottom line. Both 2024 and 2025 were loss years, making two consecutive years of losses.
The debt-to-equity ratio fell to 16.6% at end-2025 from 34.9% in 2024, with total equity of KRW 28.4 billion and total liabilities of KRW 4.73 billion. Operating cash flow worsened from negative KRW 14.7 billion in 2024 to negative KRW 22.8 billion in 2025.
Quarterly operating losses moved from KRW 10.6 billion in the third quarter of 2025 to KRW 9.57 billion, KRW 5.75 billion and KRW 4.27 billion through the second quarter of 2026, before widening to KRW 9.13 billion in the third quarter.
Controlling-shareholder net losses followed the same pattern, falling to KRW 3.9 billion in the second quarter of 2026 and rising to KRW 8.1 billion in the third quarter. Net losses attributable to controlling shareholders over the last four quarters totaled KRW 27 billion.
The reason for the renewed third-quarter widening should be checked against the expense items in the quarterly report, particularly the timing of spending on clinical expansion.